Acadian Asset Management
PCVX icon

Acadian Asset Management’s Vaxcyte PCVX Stock Holding History

Acadian Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,072
Closed -$62K – 2177
2026
Q1 		$62K Sell
1,072
-5,223
-83% -$284K ﹤0.01% 1829
2025
Q4 		$289K Sell
6,295
-78,085
-93% -$3.49M ﹤0.01% 1440
2025
Q3 		$3.04M Buy
+84,380
New +$2.8M 0.01% 778
2024
Q4 		– Sell
-6,711
Closed -$766K – 2031
2024
Q3 		$766K Buy
+6,711
New +$605K ﹤0.01% 983

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Acadian Asset Management's PCVX Position: Q2 2026 in Review

Acadian Asset Management sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 1,072 shares — an estimated $62K sold.

Acadian Asset Management first reported a position in PCVX in Q3 2024 and held it in 4 quarters. The position peaked at $3.04M in Q3 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Acadian Asset Management reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 1,072 Vaxcyte shares in Q2 2026, an estimated $62K.
  • Acadian Asset Management first reported a position in Vaxcyte in Q3 2024 and held it in 4 quarters.
  • Acadian Asset Management's Vaxcyte position peaked at $3.04M in Q3 2025.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.